A meaningful exploration of ofatumumab in refractory NMOSD: a case report

Frontiers in Immunology

Immunology

Yuanqi Zhao¹  Min Zhao¹  Haoyou Xu¹  Zhenzhen Lou²  Yibo Zhan²  Xiaojun Li²  Guixian Chen²  Haoxuan Chen²  Huiying Ouyang²  Chenghao Du² 

[1] State Key Laboratory of Dampness Syndrome of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China;Department of Neurology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China;The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China;

关键词: neuromyelitis optica spectrum disorder;    ofatumumab;    B cell depletion therapy;    relapse;    refractory;   

DOI  :  10.3389/fimmu.2023.1208017

 received in 2023-04-18, accepted in 2023-06-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

ObjectiveTo report the case of a patient with refractory neuromyelitis optica spectrum disorder (NMOSD), who, despite showing poor response or intolerance to multiple immunosuppressants, was successfully treated with Ofatumumab.Case presentationA 42-year-old female was diagnosed with NMOSD in the first episode of the disease. Despite treatment with intravenous methylprednisolone, immunoglobulin, rituximab and immunoadsorption, together with oral steroids, azathioprine, mycophenolate mofetil and tacrolimus, she underwent various adverse events, such as abnormal liver function, repeated infections, fever, rashes, hemorrhagic shock, etc., and experienced five relapses over the ensuing four years. Finally, clinicians decided to initiate Ofatumumab to control the disease. The patient received 9 doses of Ofatumumab over the next 10 months at customized intervals. Her symptoms were stable and there was no recurrence or any adverse events.ConclusionOfatumumab might serve as an effective and safe alternative for NMOSD patients who are resistant to other current immunotherapies.

【 授权许可】

Unknown   
Copyright © 2023 Zhan, Zhao, Li, Ouyang, Du, Chen, Lou, Chen, Zhao and Xu